Lupin

Lupin FCF per Share

The Free Cash Flow per Share of Lupin (LUPIN.NS) as of Oct 10, 2026 is 112.10 INR. In the previous year, Free Cash Flow per Share was 28.77 INR — a change of 289.64% (higher).

FCF per Share

112.10INR

YoY

289.64%

Last updated:

Free Cash Flow per Share of Lupin is 2026 112.10 INR. Free Cash Flow per Share of Lupin was 2025 28.77 INR. It decreases by 289.64% higher compared to the previous year.

The Lupin FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2019
15.04 INR
Jan 1, 2020
17.48 INR
Jan 1, 2021
25.13 INR
Jan 1, 2022
-11.77 INR
Jan 1, 2023
8.69 INR
Jan 1, 2024
59.44 INR
Jan 1, 2025
28.77 INR
Jan 1, 2026
112.10 INR
The Lupin FCF per Share history
YEARFCF per ShareYoY
112.10INR+289.64%
28.77INR-51.59%
59.44INR+583.88%
8.69INR-173.82%
-11.77INR-146.86%
25.13INR+43.70%
17.48INR+16.26%
15.04INR+243.43%
4.38INR-86.55%
32.57INR-123.82%
-136.70INR-432.43%
41.12INR+25.76%
32.70INR—
Access this data via the Eulerpool API

Lupin Stock analysis

What does Lupin do? Lupin Limited is an Indian pharmaceutical company specializing in generics and novel therapies. It was founded in 1968 by Dr. Desh Bandhu Gupta and has experienced rapid growth, becoming one of the leading companies in the global pharmaceutical market. The company's business model involves manufacturing and marketing generics and novel therapies for the treatment of various diseases such as cancer, diabetes, cardiovascular diseases, and respiratory diseases. Lupin operates worldwide with a wide range of partners to distribute its products in over 100 countries. The company is involved in various divisions including generics, novel therapies, biosimilars, and inhalation products. Lupin's generics division encompasses a wide range of products such as antibiotics, antidepressants, antihypertensives, and many other categories. Its novel therapies include innovative products for the treatment of diabetes, cancer, multiple sclerosis, and other chronic diseases. Lupin is also involved in the development of biosimilars, which are imitation biopharmaceuticals manufactured using living organisms. Lastly, the company offers inhalation products for the treatment of respiratory diseases such as asthma and COPD. Lupin has built an impressive product pipeline over the years, having submitted over 174 ANDA applications (for the approval of new generics) to the US FDA and introduced more than 80 new products in the Indian market. It has also established an innovative research and development center that focuses on the discovery of new molecules and the development of new therapeutic approaches. Another important feature of Lupin is its commitment to quality and sustainability. The company has received numerous awards for its product quality and environmental initiatives. In 2019, Lupin received the Sustainable Business Award from CNBC TV18. Overall, Lupin Limited is a successful and fast-growing company specializing in generics and novel therapies. It has a wide range of products and an impressive pipeline, and operates globally. Due to its commitment to quality and sustainability, Lupin Limited has also built a strong reputation among its customers and partners. Lupin is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lupin stock

Free Cash Flow per Share of Lupin is 112.10 INR in 2026.

Free Cash Flow per Share of Lupin changed from 28.77 INR to 112.10 INR, representing a 289.64% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share Lupin since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

Cash Flow — Lupin

All Key Metrics — Lupin